• Home
  • Early changes in the circulating T cells are associated with clinical outcomes after PD-L1 blockade by durvalumab in advanced NSCLC patients.

Early changes in the circulating T cells are associated with clinical outcomes after PD-L1 blockade by durvalumab in advanced NSCLC patients.

Author List
Naidus E, Bouquet J, Oh DY, Looney TJ, Yang H, Fong L, Standifer NE, Zhang L
Publication
Cancer immunology, immunotherapy : CII
Publication ID (Profile URL)
https://researcherprofiles.org/profile/165307755
Publication Year
2021
PubMed ID
33420629
Publication Title
Naidus E, Bouquet J, Oh DY, Looney TJ, Yang H, Fong L, Standifer NE, Zhang L. Early changes in the circulating T cells are associated with clinical outcomes after PD-L1 blockade by durvalumab in advanced NSCLC patients. Cancer Immunol Immunother. 2021 Jul; 70(7):2095-2102.